Tag: specialized drugs
-
Biogen to slash 1,000 jobs as it looks to save $700 million
[ad_1] Biogen Inc. BIIB, -3.58% said Tuesday that it will eliminate about 1,000 jobs as part of a broader cost-cutting initiative designed to save $700 million annually. The belt-tightening comes as the biotech company launches its Alzheimer’s treatment, Leqembi, a collaboration with Eisai Co. Ltd. ESALF, -2.36% that received full U.S. Food and Drug Administration…
-
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says
[ad_1] The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand. Citi analyst Peter Verdult took a look at the latest trends on what’s called the GLP-1 class of drugs, used for diabetes and…
-
Your family’s meat might not be antibiotic-free, despite what it says on the label
[ad_1] The U.S. Department of Agriculture is cracking down on misleading meat labels. The USDA says it will collect samples from cattle that will be marketed to consumers as “raised without antibiotics” or labeled “no antibiotics ever” to make sure the marketing claims and labels are accurate. The outcome of these tests will help the…
-
Eisai shares rise as FDA memo raises hopes for full approval of Alzheimer’s drug
[ad_1] Eisai shares 4523, +9.14% rose sharply Thursday morning after the U.S. Food and Drug Administration’s review memo on Leqembi raised expectations for full approval of the Alzheimer’s drug. The shares were recently 9.0% higher at 10,465 yen ($74.67) after rising as much as 10% earlier. The FDA on Wednesday released the briefing document ahead…